Cargando…

Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial

BACKGROUND & AIMS: Chronic abdominal pain is the primary symptom of chronic pancreatitis, but unfortunately it is difficult to treat. Vagal nerve stimulation studies have provided evidence of anti-nociceptive effect in several chronic pain conditions. We investigated the pain-relieving effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthulingam, Janusiya Anajan, Olesen, Søren Schou, Hansen, Tine Maria, Brock, Christina, Drewes, Asbjørn Mohr, Frøkjær, Jens Brøndum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909707/
https://www.ncbi.nlm.nih.gov/pubmed/33635894
http://dx.doi.org/10.1371/journal.pone.0247653
_version_ 1783655985709056000
author Muthulingam, Janusiya Anajan
Olesen, Søren Schou
Hansen, Tine Maria
Brock, Christina
Drewes, Asbjørn Mohr
Frøkjær, Jens Brøndum
author_facet Muthulingam, Janusiya Anajan
Olesen, Søren Schou
Hansen, Tine Maria
Brock, Christina
Drewes, Asbjørn Mohr
Frøkjær, Jens Brøndum
author_sort Muthulingam, Janusiya Anajan
collection PubMed
description BACKGROUND & AIMS: Chronic abdominal pain is the primary symptom of chronic pancreatitis, but unfortunately it is difficult to treat. Vagal nerve stimulation studies have provided evidence of anti-nociceptive effect in several chronic pain conditions. We investigated the pain-relieving effects of transcutaneous vagal nerve stimulation in comparison to sham treatment in chronic pancreatitis patients. METHODS: We conducted a randomised double-blinded, sham-controlled, crossover trial in patients with chronic pancreatitis. Patients were randomly assigned to receive a two-week period of cervical transcutaneous vagal nerve stimulation using the gammaCore device followed by a two-week sham stimulation, or vice versa. We measured clinical and experimental endpoints before and after each treatment. The primary clinical endpoint was pain relief, documented in a pain diary using a visual analogue scale. Secondary clinical endpoints included Patients’ Global Impression of Change score, quality of life and Brief Pain Inventory questionnaire. Secondary experimental endpoints included cardiac vagal tone and heart rate. RESULTS: No differences in pain scores were seen in response to two weeks transcutaneous vagal nerve stimulation as compared to sham treatment (difference in average pain score (visual analogue scale): 0.17, 95%CI (-0.86;1.20), P = 0.7). Similarly, no differences were seen for secondary clinical endpoints, except from an increase in the appetite loss score (13.9, 95%CI (0.5:27.3), P = 0.04). However, improvements in maximum pain scores were seen for transcutaneous vagal nerve stimulation and sham treatments as compared to their respective baselines: vagal nerve stimulation (-1.3±1.7, 95%CI (-2.21:-0.42), P = 0.007), sham (-1.3±1.9, 95%CI (-2.28:-0.25), P = 0.018). Finally, heart rate was decreased after two weeks transcutaneous vagal nerve stimulation in comparison to sham treatment (-3.7 beats/min, 95%CI (-6.7:-0.6), P = 0.02). CONCLUSION: In this sham-controlled crossover study, we found no evidence that two weeks transcutaneous vagal nerve stimulation induces pain relief in patients with chronic pancreatitis. TRIAL REGISTRATION NUMBER: The study is registered at NCT03357029; www.clinicaltrials.gov.
format Online
Article
Text
id pubmed-7909707
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-79097072021-03-05 Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial Muthulingam, Janusiya Anajan Olesen, Søren Schou Hansen, Tine Maria Brock, Christina Drewes, Asbjørn Mohr Frøkjær, Jens Brøndum PLoS One Research Article BACKGROUND & AIMS: Chronic abdominal pain is the primary symptom of chronic pancreatitis, but unfortunately it is difficult to treat. Vagal nerve stimulation studies have provided evidence of anti-nociceptive effect in several chronic pain conditions. We investigated the pain-relieving effects of transcutaneous vagal nerve stimulation in comparison to sham treatment in chronic pancreatitis patients. METHODS: We conducted a randomised double-blinded, sham-controlled, crossover trial in patients with chronic pancreatitis. Patients were randomly assigned to receive a two-week period of cervical transcutaneous vagal nerve stimulation using the gammaCore device followed by a two-week sham stimulation, or vice versa. We measured clinical and experimental endpoints before and after each treatment. The primary clinical endpoint was pain relief, documented in a pain diary using a visual analogue scale. Secondary clinical endpoints included Patients’ Global Impression of Change score, quality of life and Brief Pain Inventory questionnaire. Secondary experimental endpoints included cardiac vagal tone and heart rate. RESULTS: No differences in pain scores were seen in response to two weeks transcutaneous vagal nerve stimulation as compared to sham treatment (difference in average pain score (visual analogue scale): 0.17, 95%CI (-0.86;1.20), P = 0.7). Similarly, no differences were seen for secondary clinical endpoints, except from an increase in the appetite loss score (13.9, 95%CI (0.5:27.3), P = 0.04). However, improvements in maximum pain scores were seen for transcutaneous vagal nerve stimulation and sham treatments as compared to their respective baselines: vagal nerve stimulation (-1.3±1.7, 95%CI (-2.21:-0.42), P = 0.007), sham (-1.3±1.9, 95%CI (-2.28:-0.25), P = 0.018). Finally, heart rate was decreased after two weeks transcutaneous vagal nerve stimulation in comparison to sham treatment (-3.7 beats/min, 95%CI (-6.7:-0.6), P = 0.02). CONCLUSION: In this sham-controlled crossover study, we found no evidence that two weeks transcutaneous vagal nerve stimulation induces pain relief in patients with chronic pancreatitis. TRIAL REGISTRATION NUMBER: The study is registered at NCT03357029; www.clinicaltrials.gov. Public Library of Science 2021-02-26 /pmc/articles/PMC7909707/ /pubmed/33635894 http://dx.doi.org/10.1371/journal.pone.0247653 Text en © 2021 Muthulingam et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Muthulingam, Janusiya Anajan
Olesen, Søren Schou
Hansen, Tine Maria
Brock, Christina
Drewes, Asbjørn Mohr
Frøkjær, Jens Brøndum
Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title_full Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title_fullStr Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title_full_unstemmed Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title_short Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
title_sort cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: a randomised sham controlled clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909707/
https://www.ncbi.nlm.nih.gov/pubmed/33635894
http://dx.doi.org/10.1371/journal.pone.0247653
work_keys_str_mv AT muthulingamjanusiyaanajan cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial
AT olesensørenschou cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial
AT hansentinemaria cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial
AT brockchristina cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial
AT drewesasbjørnmohr cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial
AT frøkjærjensbrøndum cervicaltranscutaneousvagalneuromodulationinchronicpancreatitispatientswithchronicpainarandomisedshamcontrolledclinicaltrial